Bing-Neel syndrome successfully treated with venetoclax and zanubrutinib: A case report and review of the literature.

Medicine (Baltimore)Oct 23, 2026

Shenhe Jin, Yuhui Wu, Jin Zhang

✦ AI-curated · Sources linked

Case in brief

A 66-year-old woman with Waldenström macroglobulinemia presented with headache and was diagnosed with Bing-Neel syndrome after cerebrospinal fluid examination. She received zanubrutinib with venetoclax. Her symptoms resolved, and follow-up cerebrospinal fluid no longer showed abnormal B lymphocytes. Venetoclax was detected in cerebrospinal fluid.

What made this case unusual

Venetoclax was detected in cerebrospinal fluid in this case, alongside clinical and cerebrospinal fluid remission after treatment with venetoclax and zanubrutinib.

Diagnostic / clinical pearl

In a patient with Waldenström macroglobulinemia and neurological symptoms, Bing-Neel syndrome can be diagnosed through cerebrospinal fluid examination; the report highlights the diagnostic role of CSF assessment.

Why it matters

The case adds a report of remission with venetoclax plus zanubrutinib and documented venetoclax in CSF, in a condition for which the abstract notes there is no consensus standard management.

Source

Published in Medicine (Baltimore). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.